An Open-Label Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy.

Site Image

Study Overview

You are being asked to be in this study because you have epilepsy and you take epilepsy medication. Aquestive Therapeutics (the study Sponsor) has begun a research study of an investigational drug called Diazepam Buccal Soluble Film or DBSF as a possible treatment for patients with epilepsy. An investigational drug is one that has not been approved by the United States (US) Food and Drug Administration (FDA).

Study Description

Diazepam Buccal Soluble Film)is an investigational seizure rescue medication that is placed against the inside of the cheek. The film is a small thin strip and contains the medicine diazepam. It will stick to the inside of the cheek and then dissolve in a few minutes. Diazepam Buccal Soluble Film is being developed to offer patients with epilepsy another treatment option when compared to the currently available Diastat® AcuDial™ rectal gel.

The main purpose of this study is to learn about the safety of the study medication when taken to treat your seizures and how comfortable you are when you use it. This study will also look at how easy it is to use the study medication and how it may affect the
quality of your life.

  • Study Identifier: 828955

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email